Table 3 The correlations between the overall survival and various clinicopathological factors
Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
Age (≥65 vs. < 65 years) | 1.266 | 0.869–1.845 | 0.219 | |||
Gender (Female vs. Male) | 1.300 | 0.895–1.888 | 0.169 | |||
Performance status (≥1 vs. 0) | 1.847 | 1.098–3.106 | 0.021 | 1.501 | 0.767–2.936 | 0.236 |
Location of primary tumor (Right side vs. Left side) | 1.985 | 1.273–3.094 | 0.002 | 2.441 | 1.427–4.175 | 0.001 |
Histological type (Poorly, Mucinous vs. Well, Moderately) | 0.710 | 0.368–1.370 | 0.307 | |||
RAS status (Wild type vs. Mutant type) | 1.697 | 1.095–2.628 | 0.018 | 1.416 | 0.902–2.222 | 0.131 |
Detection of unresectable tumor (Synchronous vs. Metachronous) | 1.087 | 0.723–1.635 | 0.687 | |||
Number of organs affected by metastasis (≥2 vs. 1) | 1.142 | 0.770–1.693 | 0.509 | |||
Peritoneal dissemination (Positive vs. Negative) | 1.156 | 0.732–1.824 | 0.534 | |||
Molecular-targeted therapy (Absent vs. Present) | 1.148 | 0.783–1.684 | 0.480 | |||
ALI (Low vs. High) | 2.571 | 1.754–3.769 | < 0.001 | 2.773 | 1.773–4.335 | < 0.001 |